Domain Therapeutics Discloses DT-9046 as a Groundbreaking Oral Drug Candidate for Inflammatory Diseases

Domain Therapeutics France Canada United Kingdom United States of America

DT-9046 is a highly differentiated first-in-class biased negative allosteric modulator of PAR2 with game changing potential across multiple inflammatory diseases Unique mechanism of action with potential to directly impact inflammation, tissue damage, and painView original content:https://www.prnewswire.co.uk/news-releases/domain-therapeutics-discloses-dt-9046-as-a-groundbreaking-oral-drug-candidate-for-inflammatory-diseases-302406161.html